Kenvue Inc. $KVUE Stock Position Lowered by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its position in Kenvue Inc. (NYSE:KVUE) by 24.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,092,024 shares of the company’s stock after selling 351,674 shares during the quarter. Russell Investments Group Ltd. owned about 0.06% of Kenvue worth $22,851,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Vestcor Inc lifted its holdings in Kenvue by 13.6% in the 1st quarter. Vestcor Inc now owns 37,754 shares of the company’s stock valued at $905,000 after acquiring an additional 4,529 shares during the last quarter. Arkadios Wealth Advisors acquired a new position in shares of Kenvue in the 1st quarter worth approximately $442,000. US Bancorp DE raised its holdings in shares of Kenvue by 30.2% in the 1st quarter. US Bancorp DE now owns 359,597 shares of the company’s stock worth $8,623,000 after purchasing an additional 83,463 shares in the last quarter. TIAA Trust National Association acquired a new stake in Kenvue during the first quarter valued at approximately $214,000. Finally, IFG Advisory LLC lifted its stake in Kenvue by 19.4% during the first quarter. IFG Advisory LLC now owns 12,913 shares of the company’s stock valued at $310,000 after purchasing an additional 2,100 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE stock opened at $17.31 on Friday. The firm has a 50 day moving average of $16.06 and a two-hundred day moving average of $19.56. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a market capitalization of $33.15 billion, a price-to-earnings ratio of 23.07 and a beta of 0.71. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. Kenvue’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Wednesday, November 12th. Kenvue’s dividend payout ratio is 110.67%.

Analyst Ratings Changes

Several research analysts have issued reports on KVUE shares. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Royal Bank Of Canada cut their price objective on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research report on Friday, August 8th. The Goldman Sachs Group decreased their target price on Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. Deutsche Bank Aktiengesellschaft set a $18.00 target price on Kenvue in a research report on Friday, October 24th. Finally, Zacks Research raised Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat.com, Kenvue has an average rating of “Hold” and a consensus target price of $20.23.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.